doi.org/10.1007/s00109-016-1488-y Vasireddi, N., et al
Buprenorphine is probably the treatment of choice if the target is the discontinuation of opioid therapy in patients still complaining of pain, given its superiority in terms of pain control over 2 agonists
A meta-analysis of six randomized trials that compared 3 to 6 months of postoperative treatment with a gonadotropin-releasing hormone agonist (GnRH), danazol, or combined oral contraceptives with no postoperative treatment of placebo revealed a significant reduction in pain scores at the conclusion of therapy in the active-treatment groups, although the benefits were inconsistent with longer follow-up (to 18 months) after discontinuation of therapy (22)
However, oral supplementation of L-arginine, the precursor for NO synthesis, has been shown to be largely ineffective at increasing NO synthesis and/or bioavailability for several reasons, which makes L-citrulline much more ideal for boosting levels of L-arginine and subsequently NO
Factors like poor diet, environmental pollutants, and lack of sleep can further deplete these vital stores
Novel empirical disability weights to assess the burden of non-fatal injury
